生脉联合胸腺肽α_1对高龄医院获得性重症肺炎患者细胞免疫功能及预后的影响  

Effect of Shengmai injection combined with thymosin α_1 on cellular immune function and prognosis in aged patients with hospital acquired serious pneumonia

作　　者：倪杰[1] 张均[1] 房宇[1] 张龙[1] 

机构地区：[1]江苏省南京市鼓楼医院,江苏南京210008

出　　处：《现代中西医结合杂志》2012年第29期3193-3194,3204,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察和评价生脉联合胸腺肽α1对高龄医院获得性重症肺炎患者细胞免疫功能及预后的影响。方法将重症监护室内高龄医院获得性重症肺炎患者随机分为对照组和治疗组。对照组采取常规治疗,而治疗组使用常规治疗+生脉联合胸腺肽α1治疗2周。观察并比较治疗前后2组慢性健康评分系统(APACHEⅡ)评分、器官功能障碍(Mar-shall)评分、ICU住院时间及28 d病死率;采用流式细胞术检测外周血T细胞亚群(CD3+、CD4+、CD8+、CD3+/CD4+)的表达水平。结果治疗后治疗组患者CD3+、CD4+表达水平显著高于对照组,CD8+表达水平低于对照组。APACHEⅡ评分、Marshall评分均低于对照组,ICU住院时间短于对照组,但28 d病死率2组比较无显著性差异。结论生脉联合胸腺肽α1能增强高龄医院获得性重症肺炎患者的免疫防御能力,改善预后,缩短其住院时间,但未能显著降低病死率。Objective It is to observe and evaluate the effect of Shengmai injection combined with thymosin α1 on cellular immune function and prognosis in aged patients with hospital acquired serious pneumonia.Methods The aged patients with hospital acquired serious pneumonia in intensive care unit(ICU) were randomly divided into control group and therapy group.The control group was given routine therapy while the therapy group was treated with routine therapy and Shengmai injection combined with thymosin α1 for two weeks.The scores of Marshall and APACHIEⅡ,and hospitalization days in ICU and 28-day mortality were observed compared before and after treatment in both groups.The expressing levels of T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)in peripheral blood were tested by flow cytometer.Results The percentage of CD3+、CD4+ in the therapy group were obviously higher than that in control group(P<0.05),while CD8+ in the therapy group were obviously lower than that in control group(P<0.05).The scores of Marshall and APACHIEⅡ in therapy group were obviously lower than that in control group.The hospitalization days in ICU showed significant different between the two groups(P<0.05),while the 28-day mortality did not(P>0.05).Conclusion The therapy of combined use of Shengmai injection and thymosin α1 can improve the immune function and prognosis of the aged patients with hospital acquired serious pneumonia,and can decrease the hospitalization days in ICU,but it cann't significantly low down the mortality.

关 键 词：生脉 胸腺肽Α1 医院获得性肺炎 细胞免疫 

分 类 号：R563.1[医药卫生—呼吸系统]